Effects of Add-On Ultramicronized N-Palmitol Ethanol Amide in Patients Suffering of Migraine With Aura: A Pilot Study
Controlled trialHumans
- Design
- Controlled trial
- Subjects
- 20 patients with migraine with aura received the supplement added to their usual treatment. 20 served as controls. All completed.
- Dose used in the study
- 1,200 mg a day of ultramicronised palmitoylethanolamide
- Duration
- 90 days
- What was measured
- Pain on a visual analogue scale, number of attacks, days of pain per attack and use of anti-inflammatory medication
What the authors reported
The authors reported lower pain scores at 60 and 90 days in the supplement group, a fall in attacks from 3.1 to 2.0 a month, and a 50% reduction in anti-inflammatory use. The control group showed no significant change in attack frequency. No major clinical event was recorded.
Limits of this study
A single-blind pilot study with no placebo. The authors name the single blinding, the small sample and the short follow-up as limits. They declared no commercial or financial relationships.
Source
Entry checked against the full text at the publisher (Frontiers) on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.